Investor's Business Daily28d agoneutral
Eli Lilly's Market Cap Balloons Again On This IPO's SetbackEli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
527last 24h
2508last 7d
482● bullish (7d)
256● bearish (7d)
197publishers
Zacks61d agoneutral
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Motley Fool81d agobullish
Is Kailera Therapeutics a Buy After Its Sizzling IPO?There's a new challenger to the more established players in the weight-loss drug space.
Investor's Business Daily84d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.